Overview

This trial is active, not recruiting.

Condition diabetes mellitus, type 2
Treatments con, iw-60, iw-45
Sponsor Rigshospitalet, Denmark
Start date October 2015
End date June 2016
Trial size 14 participants
Trial identifier NCT02601482, H-15008542 - 2

Summary

A single bout of Interval-Walking (IW) exercise is superior to energy-expenditure and time-duration matched Continuous Walking (CW) exercise upon improving glycemic control. The time spend with high-intensity (fast) walking is considered to be responsible for the improvements seen, whereas the time spend with low-intensity (slow) walking is considered less important.

This study will assess if IW with maintained fast walking time duration but reduced total time duration (i.e. reduced slow walking time duration) is equally effective as IW with a normal time duration.

Subjects with type 2 diabetes will be included in a crossover, controlled study, where each subject will undergo three trials. Trials will be identical except the following interventions:

1. Sixty minutes of rest (CON)

2. Sixty minutes of classical interval walking (repeated cycles of 3 minutes of fast and 3 minutes of slow walking; IW-60)

3. Fourty-five minutes of time-reduced interval walking (repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking; IW-45).

After the interventions subjects will undergo a standardized mixed meal tolerance test with assessment of glycemic control.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model crossover assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
No exercise intervention.
con
(Experimental)
Sixty minutes with repeated cycles of 3 minutes of fast and 3 minutes of slow walking on a treadmill
iw-60
(Experimental)
Forty-five minutes with repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking on a treadmill
iw-45

Primary Outcomes

Measure
Glycemic control
time frame: Within the first 4 hours after the intervention

Secondary Outcomes

Measure
Matsuda insulin sensitivity index
time frame: Within the first 4 hours after the intervention
Stumvoll insulin sensitivity index
time frame: Within the first 4 hours after the intervention
Cederholm insulin sensitivity index
time frame: Within the first 4 hours after the intervention
HOMA-2 insulin resistance index
time frame: Within the first 4 hours after the intervention

Eligibility Criteria

Male or female participants at least 30 years old.

Inclusion Criteria: - Type 2 Diabetes Mellitus - BMI > 25 Exclusion Criteria: - Pregnancy - Smoking - Contraindication to increased levels of physical activity - Eating disorder - Insulin dependence

Additional Information

Official title Optimization of Interval-training in Patients With Type 2 Diabetes
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Rigshospitalet, Denmark.